AAP
IBRX icon

Ardsley Advisory Partners’s ImmunityBio IBRX Stock Holding History

Ardsley Advisory Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,000
Closed -$112K – 156
2017
Q4 		$112K Buy
+25,000
New +$118K 0.01% 133

Other funds holding IBRX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ardsley Advisory Partners's IBRX Position: Q1 2018 in Review

Ardsley Advisory Partners sold out of ImmunityBio (IBRX) in Q1 2018, closing a stake of 25,000 shares — an estimated $112K sold.

Ardsley Advisory Partners first reported a position in IBRX in Q4 2017 and held it in 1 quarter. The position peaked at $112K in Q4 2017. 62 funds tracked by Wall St. Rank hold IBRX as of Q1 2018.

  • Ardsley Advisory Partners reported no remaining ImmunityBio position as of Q1 2018 after selling out during the quarter.
  • Ardsley Advisory Partners sold 25,000 ImmunityBio shares in Q1 2018, an estimated $112K.
  • Ardsley Advisory Partners first reported a position in ImmunityBio in Q4 2017 and held it in 1 quarter.
  • Ardsley Advisory Partners's ImmunityBio position peaked at $112K in Q4 2017.
  • 62 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2018.

Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.